title: Detection of malignant primary hepatic neoplasms with gadobenate dimeglumine (Gd-BOPTA) enhanced T1-weighted hepatocyte phase MR imaging: results of off-site blinded review in a phase-II multicenter trial.
abstract: OBJECTIVE
  To investigate the efficacy of gadobenate dimeglumine (Gd-BOPTA) enhanced MR imaging for the detection of liver lesions in patients with primary malignant hepatic neoplasms.
  
  
  METHODS
  Thirty-one patients with histologically proven primary malignancy of the liver were evaluated before and after administration of Gd-BOPTA at dose 0.05 or 0.10 mmol/kg. T1-weighted spin echo (T1W-SE) and gradient echo (T1W-GRE) images were evaluated for lesion number, location, size and confidence by three off-site independent reviewers and the findings were compared to reference standard imaging (intraoperative ultrasound, computed tomography during arterial portography or lipiodol computed tomography). Results were analyzed for significance using a two-sided McNemar's test.
  
  
  RESULTS
  More lesions were identified on Gd-BOPTA enhanced images than on unenhanced images and there was no significant difference in lesion detection between either concentration. The largest benefit was in detection of lesions under 1 cm in size (7 to 21, 9 to 15, 16 to 18 for reviewers A, B, C respectively). In 68% of the patients with more than one lesion, Gd-BOPTA increased the number of lesions detected.
  
  
  CONCLUSIONS
  Liver MR imaging after Gd-BOPTA increases the detection of liver lesions in patients with primary malignant hepatic neoplasm.
authors.affiliation: The Division of Abdominal Imaging and Intervention, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
authors.forename: C S
authors.initials: CS
authors.lastname: Peña
authors.forename: S
authors.initials: S
authors.lastname: Saini
authors.forename: R L
authors.initials: RL
authors.lastname: Baron
authors.forename: B A
authors.initials: BA
authors.lastname: Hamm
authors.forename: G
authors.initials: G
authors.lastname: Morana
authors.forename: R
authors.initials: R
authors.lastname: Caudana
authors.forename: A
authors.initials: A
authors.lastname: Giovagnoni
authors.forename: A
authors.initials: A
authors.lastname: Villa
authors.forename: A
authors.initials: A
authors.lastname: Carriero
authors.forename: D
authors.initials: D
authors.lastname: Mathieu
authors.forename: M W
authors.initials: MW
authors.lastname: Bourne
authors.forename: M A
authors.initials: MA
authors.lastname: Kirchin
authors.forename: G
authors.initials: G
authors.lastname: Pirovano
authors.forename: A
authors.initials: A
authors.lastname: Spinazzi
mesh_terms: D018248:Adenoma, Liver Cell / Q000175:diagnosis*; D000328:Adult; D000368:Aged; D003287:Contrast Media; D005260:Female; D006801:Humans; D007089:Image Enhancement; D008113:Liver Neoplasms / Q000175:diagnosis*; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008297:Male; D008536:Meglumine / Q000031:analogs & derivatives*; D008875:Middle Aged; D009942:Organometallic Compounds
chemical_list: D003287:Contrast Media; D009942:Organometallic Compounds; C064572:gadobenic acid; D008536:Meglumine